-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a new study by the American Heart Association journal Circulation: Genomic and Precision Medicine, there are significantly more standard tests for predicted early heart disease based on multiple genetic differences or multigene risk scores than for a single genetic defect. "Our findings provide compelling evidence that multigene risk scores can be added to genetic surveys in very early coronary artery disease patients," said lead author of the
study. "Heart disease is the leading cause of death in the United States and around the world,
. The most common form of
is coronary artery disease, which occurs when the heart's blood vessels are stenosis or hardens.
most people can reduce risk by not smoking, physical activity, maintaining a healthy diet and weight, and controlling cholesterol, blood pressure and blood sugar.
However, in rare cases, high blood levels of LDL, the so-called bad cholesterol, are caused by genetic defects caused by familial hypercholesterolemia (FH).
an increased risk of early heart disease in patients with this genetic defect, and early diagnosis and treatment are critical in the study, which is defined as a 40-year-old for men and 45 years for women.
problem is that many patients with early-onsis heart disease do not have this single genetic defect, which can be measured by current tests.
Therefore, this study looked at the relationship between risk scores based on multiple genetic differences and early onset heart disease.
results showed that the multigene risk score predicted a 53 percent risk of early-ons heart disease, the same as FH.
the incidence of FH is one in 256 people for a single genetic test for FH. "Increased genetic risk is independent of other known risk factors, suggesting that tests for multiple genetic differences clinically contribute to risk assessment and guidance management," said senior author Dr Guillaume Par?
he is an associate professor at McMaster University School of Medicine and director of the Genetic and Molecular Epidemiology Laboratory at hamilton School of Health Sciences in Hamilton, Ontario, Canada.
", "combining multigene screening with current familial hypercholesterolemia tests may increase the genetic explanation that could be used to detect cases."
" researchers developed multigene risk scores based on 182 genetic differences associated with coronary artery disease.
they then compared multigene risk scores among study participants who had and did not have early heart disease.
study participants included 30 cases of early-onsis heart disease found in researchers' clinics from 2014 to 2016.
patients with no high multigene risk score in this study did not have a single, rare FH genetic defect.
the Biobank study in the UK included 96 patients with early-onsis between 2006 and 2010.
, the study also included 111,283 Biobank participants who did not have an early heart attack.
47 per cent of UK Biobank participants were men, with an average age of 58.
the UK's biobank is a major study of the relationship between genetics, the environment and disease.
all of the study participants were of European descent, the results may not be applicable to other groups of people. Another limitation of
is the inclusion of patients with severe early-onset heart disease, which is more likely to have a genetic disorder than a mild disease.
Source: Decoding Medicine.